British consumer healthcare group Haleon has emerged as a potential buyer for Thorne, a US-based supplements brand that has caught the eye of major players in the wellness space. According to a Reuters report on June 26th, Haleon is among the companies circling Thorne as its owner, private equity firm L Catterton, considers a possible sale.
L Catterton, which is backed by luxury goods giant LVMH, has not yet decided whether to run a full sale process, meaning no deal is guaranteed. But Haleon’s interest signals a clear strategic shift: consumer health companies are increasingly looking to add “wellness” brands that can command higher profit margins and generate repeat purchases from health-conscious shoppers.
What is Thorne and Why Does It Matter?
Thorne is a US-based maker of dietary supplements, including vitamins, minerals, and other health products. The brand has built a reputation for quality and science-backed formulations, making it a favorite among athletes, wellness enthusiasts, and healthcare practitioners. In a market where consumers are spending more on preventive health, Thorne has seen steady growth.
For Haleon, which was spun off from pharmaceutical giant GSK in 2022, acquiring Thorne would fit neatly into its portfolio of consumer health brands like Advil, Sensodyne, and Centrum. The company has been looking to expand its presence in the fast-growing supplements category, which offers higher margins than many traditional over-the-counter medicines.
Haleon vs. Unilever: A Tale of Two Bidders
The Reuters report also noted that Unilever, another consumer goods giant, is not among the bidders for Thorne. This is a notable development, as Unilever had previously been linked to a potential $4 billion deal for the supplements brand. The company has been actively reshaping its portfolio toward higher-growth categories like health and beauty, but it appears to have stepped back from this particular opportunity.
Haleon’s interest comes amid a broader wave of dealmaking in the consumer health sector. Companies are racing to acquire brands that can tap into the growing demand for wellness products, especially as consumers become more proactive about their health. The trend is not limited to supplements: dealmakers have been busy across multiple industries, with firms like Safran and ON Semiconductor also pursuing acquisitions.
What It Means for Investors
For everyday investors, the potential acquisition of Thorne by Haleon is a reminder of the shifting dynamics in the consumer health space. Here are a few key takeaways:
- Wellness is big business: The supplements market is growing rapidly, driven by aging populations, rising health awareness, and a shift toward preventive care. Companies that can capture this trend may see stronger revenue growth and higher margins.
- M&A activity can signal sector strength: When major players like Haleon and L Catterton are circling a brand like Thorne, it often indicates that the broader category is seen as attractive. Investors may want to keep an eye on other companies in the wellness space.
- No deal is done yet: The sale process is still in its early stages, and L Catterton may decide not to sell at all. Investors should avoid making decisions based on rumors alone.
It’s also worth noting that Haleon’s move comes at a time when consumer spending is under scrutiny. Recent data showed that US Q1 growth was revised up to 2.1%, but consumer spending slumped to 0.5%, suggesting that shoppers are becoming more cautious. However, wellness products often prove resilient even in tough economic times, as consumers prioritize health over discretionary purchases.
What to Watch Next
Investors should monitor whether L Catterton decides to proceed with a formal sale process and whether other bidders emerge. If a deal is reached, it could set a valuation benchmark for other supplements brands and potentially spark further M&A in the sector.
For now, Haleon’s interest in Thorne is a clear sign that the company is serious about expanding its wellness footprint. Whether it succeeds will depend on the outcome of negotiations and the broader appetite for deals in the consumer health space.
